Penserra Capital Management’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Penserra Capital Management’s Portfolio FOMX Stock Details FOMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-7,217	Closed	-$35K	–	606
2017 Q1	$35K	Buy	7,217 +3,093	+75%	+$29.8K	﹤0.01%	352
2016 Q4	$45K	Buy	4,124 +68	+2%	+$640	0.01%	406
2016 Q3	$37K	Buy	4,056 +1,014	+33%	+$8.47K	﹤0.01%	380
2016 Q2	$19K	Buy	3,042 +369	+14%	+$2.45K	﹤0.01%	479
2016 Q1	$17	Buy	2,673 +891	+50%	+$5.75K	﹤0.01%	466
2015 Q4	$14K	Buy	+1,782	New	+$13.3K	﹤0.01%	471

Other funds holding FOMX

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Penserra Capital Management's FOMX Position: Q2 2017 in Review

Penserra Capital Management sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q2 2017, closing a stake of 7,217 shares — an estimated $35K sold.

Penserra Capital Management first reported a position in FOMX in Q4 2015 and held it in 6 quarters. The position peaked at $45K in Q4 2016. 56 funds tracked by Wall St. Rank hold FOMX as of Q2 2017.

Penserra Capital Management reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q2 2017 after selling out during the quarter.
Penserra Capital Management sold 7,217 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q2 2017, an estimated $35K.
Penserra Capital Management first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q4 2015 and held it in 6 quarters.
Penserra Capital Management's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $45K in Q4 2016.
56 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q2 2017.

Based on Penserra Capital Management's 13F filing for Q2 2017, filed 7 Aug 2017.